Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Amazon Explores AI Content Marketplace With Media Publishers 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
NEW YORK, March 14, 2018 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Synergy Pharmaceuticals Inc. ("Synergy") (NASDAQ:SGYP) between November 10, 2016 and November 14, 2017. You are hereby notified that securities class action lawsuits have been commenced in the USDC for the Eastern District of New York. To get more information go to:
http://www.zlk.com/pslra-d/synergy-pharmaceuticals-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaints allege that throughout the class periods Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) the loan from CRG Partners III L.P. (“CRG Loan”) did not fund Synergy’s operations through 2019; (2) the Company could not access the second tranche of $100 million financing on or before February 28, 2018 without issuing dilutive equity; and (3) the Company could not access the third tranche of the CRG Loan if and when needed because terms were required to be met in order to access those tranches.
If you suffered a loss in Synergy you have until April 10, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
